Skip to main content

BaseLaunch startup Polyneuron raises new financing

Ruben Herrendorff, CEO Polyneuron Pharmaceuticals
| News

BaseLaunch startup Polyneuron raises new financing

14.05.2018

Polyneuron Pharmaceuticals has successfully raised over 3 million Swiss francs in a financing round. The Basel-based pharmaceutical company is developing an active substance for the treatment of the autoimmune disease anti-MAG neuropathy, among others.

Ruben Herrendorff, CEO Polyneuron Pharmaceuticals
Ruben Herrendorff, CEO Polyneuron Pharmaceuticals

Polyneuron Pharmaceuticals has announced the closing of a 3.1 million Swiss franc financing round. The financing was led by EVA Basel, which specializes in supporting startups, and included the Zürcher Kantonalbank and private investors.

The Basel-based pharmaceutical company will use the proceeds to advance its lead candidate, PN-1007, to clinical development for the treatment of the autoimmune disease anti-MAG neuropathy. It will also advance its Antibody-Catch technology platform, which enables the development of drugs that eliminate autoimmune-disease causing autoantibodies, while leaving the immune system intact.

Since the initial seed financing tranche, the company has met several key milestones, said CEO Ruben Herrendorff. For instance, it delivered a preclinical proof of principle with PN-1007, concluded a key licensing agreement with the University of Basel, and expanded its team – including the appointments of Gerhard Müller as Chairman and Michael Wacker as Chief Business Officer. Wacker is the co-founder, Chief Scientific Officer and member of the board of directors of the Schlieren-based company GlycoVaxyn, which was acquired by the UK’s GlaxoSmithKline in 2015.

Polyneuron Pharmaceuticals was founded in 2014 as a spin-off of the University of Basel and is headquartered in the startup centre Basel Inkubator.

Polyneuron Pharmaceuticals is part of the startups that were selected for Phase II of the BaseLaunch accelerator program.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.